NCT05058976View on ClinicalTrials.gov

Romosozumab Use to Build Skeletal Integrity

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
OsteoporosisOsteoporosis, PostmenopausalOsteoporosis Fracture
Interventions
DRUG

Romosozumab

Monthly dose: 210 mg subcutaneous injection

DRUG

Placebo

Monthly saline injection

DRUG

Zoledronic acid

5 mg IV infusion at Month 12 Visit

DIETARY_SUPPLEMENT

Calcium and Vitamin D

Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)

Trial Locations (1)

15213

UPMC Senior Communities, Pittsburgh

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Aging (NIA)

NIH

lead

Susan L. Greenspan

OTHER